Constitutional promoter methylation and risk of familial melanoma

Epigenetics

Volumn 9, Issue 5, 2014, Pages 685-692

  Hyland, Paula L ^a   Burke, Laura S ^a   Pfeiffer, Ruth M ^a   Rotunno, Melissa ^a   Sun, David ^a   Patil, Prasad ^a   Wu, Xiaolin ^b   Tucker, Margaret A ^a   Goldstein, Alisa M ^a   Yang, Xiaohong Rose ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

CDKN2A; Familial melanoma; Peripheral blood mononuclear cells; Promoter methylation; TNFRSF10C

Indexed keywords

CADHERIN; COLLAGEN TYPE 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GENOMIC DNA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HEAT SHOCK PROTEIN; MELANOMA ANTIGEN 3; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN LYSINE 6 OXIDASE; PROTEIN P16; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; UNCLASSIFIED DRUG; UVOMORULIN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; TNFRSF10C PROTEIN, HUMAN; TUMOR NECROSIS FACTOR DECOY RECEPTOR;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CELL ADHESION; CELL MIGRATION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; CPG ISLAND; CUTANEOUS MELANOMA; DNA DAMAGE; DNA EXTRACTION; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE LOCUS; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MICROARRAY ANALYSIS; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; TUMOR SUPPRESSOR GENE; AGED; CASE CONTROL STUDY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK; SKIN TUMOR;

ADULT; AGED; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; FEMALE; GENES, P16; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; GPI-LINKED PROTEINS; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RISK; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 84899839841     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.28151     Document Type: Article

References (31)

1. Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol 2001; 137:1493-6. PMID:11708953; http://dx.doi.org/10.1001/archderm.137.11.1493
2. Goldstein AM. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 2004; 23:630. PMID:15146471; http://dx.doi.org/10.1002/humu.9247
3. Chan TL, Yuen ST, Kong CK, Chan YW, Chan AS, Ng WF, Tsui WY, Lo MW, Tam WY, Li VS, et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 2006; 38:1178-83. PMID:16951683; http://dx.doi.org/10.1038/ng1866
4. Hitchins MP, Wong JJ, Suthers G, Suter CM, Martin DI, Hawkins NJ, Ward RL. Inheritance of a cancerassociated MLH1 germ-line epimutation. N Engl J Med 2007; 356:697-705. PMID:17301300; http://dx.doi.org/10.1056/NEJMoa064522
5. Yang XR, Pfeiffer RM, Wheeler W, Yeager M, Chanock S, Tucker MA, Goldstein AM. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. Int J Cancer 2009; 125:2912-7. PMID:19626699; http://dx.doi.org/10.1002/ijc.24622
6. Browne EP, Punska EC, Lenington S, Otis CN, Anderton DL, Arcaro KF. Increased promoter methylation in exfoliated breast epithelial cells in women with a previous breast biopsy. Epigenetics 2011; 6:1425-35. PMID:22139572; http://dx.doi.org/10.4161/epi.6.12.18280
7. Tran A, Escovedo C, Migdall-Wilson J, Chou AP, Chen W, Cloughesy T, Nelson S, Lai A. In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays. Front Neurosci 2009; 3:57. PMID:20582289
8. Erlandson A, Appelqvist F, Enerbäck C. Epigenetic mutations in CDKN2A in western Swedish families with hereditary malignant melanoma. Mol Med Rep 2008; 1:89-91. PMID:21479383
9. Liang KY, Zeger SL. Longitudinal Data-Analysis Using Generalized Linear-Models. Biometrika 1986; 73:13-22; http://dx.doi.org/10.1093/biomet/73.1.13
10. Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, Wong M, Sloan CA, Rosenbloom KR, Roe G, Rhead B, et al. The UCSC Genome Browser database: extensions and updates 2013. Nucleic Acids Res 2013; 41:D64-9. PMID:23155063; http://dx.doi.org/10.1093/nar/gks1048
11. Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosisinducing ligand (TRAIL) in human melanoma cells. J Immunol 2000; 164:3961-70. PMID:10754286
12. Hersey P, Zhang XD. How melanoma cells evade trail-induced apoptosis. Nat Rev Cancer 2001; 1:142-50. PMID:11905805; http://dx.doi.org/10.1038/35101078
13. Palmer C, Diehn M, Alizadeh AA, Brown PO. Celltype specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics 2006; 7:115. PMID:16704732; http://dx.doi.org/10.1186/1471-2164-7-115
14. Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA. Association of MC1R variants and risk of melanoma in melanomaprone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 2005; 14:2208-12. PMID:16172233
15. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000; 92:1006-10. PMID:10861313; http://dx.doi.org/10.1093/jnci/92.12.1006
16. Roeder C, Schuler-Thurner B, Berchtold S, Vieth G, Driesch Pv, Schuler G, Lüftl M. MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol Res 2005; 296:314-9. PMID:15570431; http://dx.doi.org/10.1007/s00403-004-0527-7
17. Marini A, Mirmohammadsadegh A, Nambiar S, Gustrau A, Ruzicka T, Hengge UR. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma. J Invest Dermatol 2006; 126:422-31. PMID:16374457; http://dx.doi.org/10.1038/sj.jid.5700073
18. Lahtz C, Stranzenbach R, Fiedler E, Helmbold P, Dammann RH. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J Invest Dermatol 2010; 130:620-2. PMID:19798057; http://dx.doi.org/10.1038/jid.2009.226
19. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, Thompson JF, Screaton G, Hersey P. Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Hum Pathol 2006; 37:1286-94. PMID:16949935; http://dx.doi.org/10.1016/j.humpath.2006.04.026
20. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res 2004; 64:9167-71. PMID:15604288; http://dx.doi.org/10.1158/0008-5472.CAN-04-1442
21. Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 2008; 21:545-58. PMID:18627528; http://dx.doi.org/10.1111/j.1755-148X.2008.00484.x
22. Bonazzi VF, Nancarrow DJ, Stark MS, Moser RJ, Boyle GM, Aoude LG, Schmidt C, Hayward NK. Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. PLoS One 2011; 6:e26121. PMID:22028813; http://dx.doi.org/10.1371/journal.pone.0026121
23. Koga Y, Pelizzola M, Cheng E, Krauthammer M, Sznol M, Ariyan S, Narayan D, Molinaro AM, Halaban R, Weissman SM. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res 2009; 19:1462-70. PMID:19491193; http://dx.doi.org/10.1101/gr.091447.109
24. Furuta J, Umebayashi Y, Miyamoto K, Kikuchi K, Otsuka F, Sugimura T, Ushijima T. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 2004; 95:962-8. PMID:15596045; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03184.x
25. Mirmohammadsadegh A, Marini A, Nambiar S, Hassan M, Tannapfel A, Ruzicka T, Hengge UR. Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006; 66:6546-52. PMID:16818626; http://dx.doi.org/10.1158/0008-5472.CAN-06-0384
26. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004; 23:4014-22. PMID:15064737; http://dx.doi.org/10.1038/sj.onc.1207505
27. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003; 63:1639-43. PMID:12670917
28. Saferali A, Grundberg E, Berlivet S, Beauchemin H, Morcos L, Polychronakos C, Pastinen T, Graham J, McNeney B, Naumova AK. Cell culture-induced aberrant methylation of the imprinted IG DMR in human lymphoblastoid cell lines. Epigenetics 2010; 5:50-60. PMID:20026906; http://dx.doi.org/10.4161/epi.5.1.10436
29. Wong CM, Anderton DL, Smith-Schneider S, Wing MA, Greven MC, Arcaro KF. Quantitative analysis of promoter methylation in exfoliated epithelial cells isolated from breast milk of healthy women. Epigenetics 2010; 5:645-55. PMID:20716965; http://dx.doi.org/10.4161/epi.5.7.12961
30. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK, Risk JM. Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer 2006; 94:561-8. PMID:16449996; http://dx.doi.org/10.1038/sj.bjc.6602972
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8. PMID:11846609; http://dx.doi.org/10.1006/meth.2001.1262